Results 81 to 90 of about 1,457,553 (300)

Genome-wide identification of wheat Ubiquitin-conjugating enzyme gene family and its role in wheat powdery mildew disease resistance

open access: yesBMC Plant Biology
Ubiquitin-conjugating enzyme (UBC) E2 is a critical component of the ubiquitination process. It interacts with the RING domain of E3 ligases through its UBC domain, enables specific identification of substrate proteins, thereby plays a pivotal role in ...
Ping Hu   +10 more
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Circular RNA-mediated inverse prime editing in human cells

open access: yesNature Communications
Prime editors are restricted to performing precise edits downstream of cleavage sites, thereby limiting their editing scope. Therefore, we develop inverse prime editors (iPEs) that act upstream of the nickase cleavage site by replacing nCas9-H840A with ...
Ronghong Liang   +9 more
doaj   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

open access: yesMolecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner   +14 more
wiley   +1 more source

Comparative evaluation of four exome enrichment solutions in 2024: Agilent, Roche, Vazyme and Nanodigmbio

open access: yesBMC Genomics
Whole exome sequencing (WES) is essential for identifying genetic variants linked to diseases. This study compares available to date four exome enrichment kits: Agilent SureSelect Human All Exon v8, Roche KAPA HyperExome, Vazyme VAHTS Target Capture Core
Vera Belova   +12 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

In-vitro genome editing: no chance for a moratorium?

open access: yes, 2019
A 18-strong group of scientists from seven countries, including the US, China and several European countries, published a statement on March 14th in the science journal Nature calling for a moratorium on heritable genome editing. This document highlights
Guillaume Levrier
core  

Integrating genome editing with omics, artificial intelligence and advanced farming technologies to increase crop productivity [PDF]

open access: yes
Celebrated for boosting agricultural productivity and enhancing food security worldwide, the green revolution constituted some of the most significant advances in crop production within the 20th century.
Biacsi, Anna-Sara   +15 more
core   +1 more source

Adenoviral Vectors for Gene Therapy of Hereditary Diseases

open access: yesBiology
Adenoviral vectors (AdVs) are effective vectors for gene therapy due to their broad tropism, high capacity, and high transduction efficiency, which makes them actively used as oncolytic vectors and for creating vector vaccines.
Anna Muravyeva, Svetlana Smirnikhina
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy